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Abstract
Dientamoeba fragilis is an enteric protozoan parasite that remains neglected, probably due
to the misconception that it is uncommon and non-pathogenic. As more information be‐
came available and antimicrobial agents were developed with activity against this para‐
site, it became clear that D. fragilis is responsible of an active infection, associated with
symptoms such as abdominal pain and diarrhea. The clinical presentation of dientamoe‐
biasis varies from asymptomatic carriage to symptoms ranging from altered bowel mo‐
tions, abdominal discomfort, nausea and diarrhea with associated eosinophilia reported
in up to 50% of paediatric and 10% of adult patients. Moreover, controversy exists over
the protective role of the parasite in priming the immune system in a beneficial way such
as in selecting beneficial bacteria, keeping potential harmful microbial intruders at bay or
producing metabolites beneficial to the host. Thus, a number of ambiguities and obscuri‐
ties surrounding D. fragilis infections exist. Moreover, the means by which this parasite is
transmitted has not been fully defined. The diagnostic recognition of this parasite in fecal
examinations requires specific processing and expertise; thus, it is possible that many in‐
fections with D. fragilis may go undiagnosed. A number of studies conducted on small
numbers of case reports have demonstrated parasite clearance, as well as resolution of
clinical symptoms following treatment with various antiparasitic compounds such as pa‐
romomycin, hydroxyquinolines and the 5-nitroimidazoles, including metronidazole and
tinidazole. In addition there is very little in vitro susceptibility data available for the or‐
ganism making some current treatment options questionable. This chapter reviews the
scientific literature relating to Dientamoeba's life cycle, prevalence, diagnosis and patho‐
genicity.
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1. Introduction
Dientamoeba fragilis is an enteric protozoan parasite that remains obscure and neglected. While
many infections remain asymptomatic, it is now generally accepted that D. fragilis is account‐
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able for an active infection, concomitant with abdominal symptoms, nausea, and diarrhea.
Moreover, controversy exists over the protective role of the parasite in priming the immune
system in a beneficial way such as in selecting beneficial bacteria, keeping potential harmful
microbial intruders at bay or producing metabolites beneficial to the host. Furthermore, the
parasite’s transmission mode remains a mystery. The microscopic identification and diagnoses
of D. fragilis in stool requires skill and expertise; consequently, it is likely that many infections
may go unidentified. Numerous studies have reported the effectiveness of treatment regimens
using compounds such as paromomycin, hydroxyquinolines, and 5-nitroimidazoles, includ‐
ing metronidazole and tinidazole in the parasite eradication and the resolution of clinical
symptoms. In addition, there is very little in vitro susceptibility data available for this parasite,
making some current treatment options questionable. This chapter reviews the scientific
literature relating to Dientamoeba’s life cycle, prevalence, diagnosis, and pathogenicity.
2. Recognition D. fragilis as a pathogen
D. fragilis is a ubiquitous protozoan parasite found in the gastrointestinal tract of humans.
Electron microscopy [1] and molecular phylogenetic studies of the SSU rRNA gene [2,3] have
recently confirmed the relationship of this parasite to trichomonads (lacking flagella). Al‐
though its pathogenic potential is still controversial, Jepps and Dobell in1918 were the first to
report its pathogenicity when it was found to be the only agent detected in three patients with
gastrointestinal clinical symptoms [5].
Figure 1. Trophozoite of D. fragilis stained by iron hematoxylin stain (Photo by Adnan Al-Hindi, 2005). Photo extracted
from Al-Hindi and Abu Shammala, 2013 [4].
Since then, many investigators have shown that patients infected with D. fragilis generally
presented with bowel disorders with symptoms such as diarrhea, loose stools, and epigastric
abdominal pains [6–12]. Furthermore, mounting evidence is accumulating reinforcing the
pathogenic potential of D. fragilis [13–20]. Lately, irritable bowel syndrome (IBS) has been linked
to D. fragilis infections as a possible cause [21, 22], further underscoring its role in the causa‐
tion of disease. A great deal of controversy exists on the mode of transmission of D. fragilis, and
while Enterobius vermicularis nematode has been accepted to play a role in its transmission, more
recently a report described the discovery of a new cyst stage in its life cycle [23].
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Globally, the prevalence rates of D. fragilis infections vary depending on the identification tool
used [6, 24, 25, 26]. Using the traditional light microscope, the rates of infections oscillate
between 0.4% and 52% [26]. Nevertheless, using indirect immunoflourescent assay, Chan et
al. (1996) reported a prevalence rate of 91% [27]. The application of more sensitive identification
tools such as PCR and culture has the extra advantage of providing accurate prevalence data
[28]. Considered as a pathogen by several researchers, numerous reports have revealed that
D. fragilis elimination with parasitic drugs normally relieves the clinical symptoms in the
absence of other pathogens. However, there is currently no consensus as to the ideal treatment
regimen [20, 29, 30]. The aim of this chapter is to review the recent developments and advances
made on this frequently overlooked parasite and the disease dientamoebiasis.
3. Biology and life cycle of D. fragilis
Ranging in size from 5 to 15 μm in diameter, D. fragilis is a single-celled pleiomorphic troph‐
ozoite containing up to four nuclei [32, 20]. A large proportion of D. fragilis trophozoites are
typically binucleated with a large, fragmented, central karyosome without peripheral chro‐
matin differentiated clearly in stained fecal smears [32,10]. Banik et al. (2012) have recently
extensively described the surface structures and ultrasrtuctural details of D. fragilis popula‐
tions grown in xenic culture [31]. Using the scanning electron microscope, the group reported
the existence of two different trophozoite populations—smooth and ruffled cells. Whether this
represents a significant difference biologically or even in terms of the parasite’s pathogenicity
remains to be elucidated. Using the transmission electron microscope, neither mitochondria
nor peroxisomes were reported [33, 34]. Nevertheless, a conspicuous organelle detected was
the hydrogenosomes. Like many other organisms living in oxygen-deprived or anaerobic
environments, these hydrogenosomes most probably represent the site of anaerobic respira‐
tion and energy production [35–39]. Different activities such as amoeboid movement, phago‐
cytosis, and bacterial adhesion to trophozoite surfaces were also reported by Banik and others
(2012) [31]. Like many other parasitic protozoa such as Trichomonas vaginalis [40, 41, 33], Giardia
[42], and Leishmania [43], virus-like particles (VLPs) have also been reported to be seen in D.
fragilis trophozoites. Many groups have reported an association between the presence of VLPs
within T. vaginalis and variations in protozoa phenotypes, virulence factors, and disease
pathogenesis [44–46]. More details of the ultrastructure of D. fragilis are available in a review
authored by Banik et al. (2012) [31].
The complete life cycle and the mode of transmission of D. fragilis remain ambiguous and
equivocal. The only known stage thus far is the trophozoite (Fig. 2). Dobell (1940) was the first
to predict E. vermicularis egg to act as a vector for the transmission of D. fragilis [47]. Recently,
Roser et al. (2013) have detected D. fragilis DNA inside E. vermicularis eggs agreeing with the
prediction of Dobell in 1940 [48]. While many reports of a higher than anticipated rate of co-
infection between D. fragilis and E. vermicularis led researchers to postulate E. vermicularis as
the probable vector responsible for its transmission [48, 49], other groups have proved no co-
infections with D. fragilis and other worms, suggesting fecal-oral transmission as the possible
mechanism of transmission of D. fragilis [9, 10]. A new study by Munasinghe et al. (2013) using
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rodents and mice infected with human isolates reported the discovery of a new cyst stage in
the life cycle of D. fragilis strongly suggesting oral–fecal transmission as the possible route of
infection [23]. Moreover, Stark et al. (2014) have recently reported a cyst form of D. fragilis from
human clinical samples, further supporting that cysts are likely to be the transmission forms
[50]. The role of animals and zoonotic transmission of the parasite is still ambiguous despite
a recent study reporting pigs and sheep as natural hosts of dientamoebiasis [51]. The reader is
invited to read an excellent review on the topic written by Clark et al. (2014) [52].
4. Epidemiology of dientamoebiasis and its occurrence
Since its hypothetical association with IBS and other bowel disorders, probable pathogenicity,
and the existence of gaps in its life cycle and mode of transmission, many investigators have
become increasingly aware of the importance of D. fragilis. This has led to the development of
more sensitive diagnostic techniques for its proper identification and determination of its
accurate prevalence. It is now recognized as being more prevalent than Giardia [7, 11, 25, 27,
29, 53–65]. Table 1 shows the prevalence rates of D. fragilis ranging between 0.3% and 90% in
many countries worldwide. With the exception of few studies, light microscopy was the tool
used in those studies. The use of more sensitive techniques such as PCR or cultivation may
result in different and more accurate prevalence rates [10, 28, 66]. Unlike many parasitic
Figure 2. Life cycle of D. fragilis. Reproduced from: Centers for Disease Control and Prevention. DPDx: Dientamoeba
fragilis infection. Available at: http://www.cdc.gov/dpdx/dientamoeba/index.html.
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infections, D. fragilis has been shown to have high infection rates in developed countries than
in underprivileged countries [25, 67].
Prevalence Sample source and type Number of
patients
Country/region Reference
36.25% Mental asylum residents; feces 80 Holland [68]
2.4 Patients; feces 14203 USA [69]
20.1% Gastrointestinal tract patients; feces 1114 Israel [70]
Not disclosed Ascaris lumbricoides patients; feces N/A Thailand [71]
About 4.2% Fecal specimens submitted for parasitological
examination
43029 Canada [16]
9.6% Fecal specimens infected with Entamoeba
histolytica/dispar
125 Mexico City, Mexico [72]
1.1% School children; feces 94 Durban, South Africa [73]
52% Adults; feces 81 Los Angeles, USA [53]
21.1% Children attending clinics; feces 104 Los Angeles, USA [74]
8.6% Children in day care centers; feces 900 Toronto, Canada [65]
4 Adults in day care centers; feces 146 Toronto, Canada [65]
1.3% Homosexual men; feces 150 San Francisco, USA [75]
16.8% Intestinal tract patients; feces 125 French’s Forest,
Sydney, Australia
[62]
1.1% Homosexual men; diarrhea 274 Chicago, USA [76]
21% Indigenous individuals; feces 242 Irian Jaya, Indonesia [77]
3% Patients with bowel disorder; feces 1350 Christchurch, New
Zealand
[78]
82.9% Children infected with other gut protozoa; feces123 Germany [64]
3% Children living in rural areas; feces 266 Honduras [79]
2% Fecal specimens with light to moderate
dehydration and diarrhea
100 Dominican Republic [80]
1.5% Patients with diarrhea 260 Brisbane, Australia [81]
25.6% HIV-positive patients with no diarrhea; feces 82 Buenos Aires,
Argentina
[82]
2.3% Children refugees; feces 87 USA [83]
91% Healthy children; sera 189 Canada [27]
Around 8% Patients with bowel symptoms N/A Netherlands [84]
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Prevalence Sample source and type Number of
patients
Country/region Reference
2.1% HIV negative patients; feces 48 San Pedro Sula,
Honduras
[85]
5.1% Routine testing; feces 857 Oman [59]
5.5% Fecal specimens submitted to a university
hospital in Tunisia
27053 Sfax, Tunisia [86]
3% HIV-positive patients; feces 34 North Brazil [87]
11.3% Gastrointestinal tract patients; feces 151 Italy [61]
8.8% Admitted patients; feces 400 Turkey, Celal Bayar
University
[29]
0.9% Diarrhea patients; feces 6750 Sydney, Australia [9]
0.82% Sanitary employees; feces 241 Malatya, Turkey [88]
6.3% Patients infected with a gut parasite; feces 448 Brussels, Belgium [6]
3.7% Gastrointestinal tract patients; feces 3139 Italy [58]
3.4% Gastrointestinal tract patients; feces 1141 Italy [57]
4.1% Gastrointestinal tract patients; feces 1989 Italy [53]
2% Children and neonates patients; feces 350 Surt, Libya [89]
2.7% Aborigines; feces 112 Salta, Argentina [90]
2.7% Feces 770 Turkey [91]
8.9% Patients infected with gut parasites; feces 168 Egypt [24]
29.8% Patients infected with gut parasites; feces 168 Egypt [24]
0.8% HIV negative MSMa; feces 628 Sydney, Australia [92]
0.3% HIV-positive MSM; feces 618 Sydney, Australia
1.1% Non-MSM patients; feces 622 Sydney, Australia
11.7% Patients suspected of infection with gut
parasites; feces
103 Denmark [25]
32% Bowel complaints patients; feces 397 Zwolle, The
Netherlands
[93]
14.6%; 16.9% Individuals attending complimentary health
care practices (2002–2004 and 2005–2007); feces
3719; 2491 British Isles [67]
0.2% School children; feces 2975 Van Province, Turkey [94]
5.2% Bowel complaints; feces 750 Sydney, Australia [11]
1.6% Digestive disorder patients; feces 8313 Catalonia, Spain [95]
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Prevalence Sample source and type Number of
patients
Country/region Reference
21.4% Patients suspected of infection with gut
parasites; feces
491 Parma, Italy [96]
3.5% Irritable bowel syndrome patients with
diarrhea; feces
171 Karachi,
Pakistan
[97]
4% Irritable bowel syndrome patients with
diarrhea; feces
171 Karachi, Pakistan
4% Irritable bowel syndrome patients with
diarrhea; feces
171 Karachi, Pakistan
5.5% Fecal samples submitted to the Department of
Microbiology at St Vincent’s Hospital, Sydney
472 Sydney, Australia [98]
8.8% Patients with clinical symptoms, like diarrhea
and abdominal pain; feces
319 Al-Nuseirate Refugee
Camp Clinic, Gaza
Strip
[4]
0% Fecal samples from different laboratories 1000 Tabriz, Iran []
2.1%b
2.4%
Table adapted from Barratt et al. 2011. With kind permission from Dr. Damien Stark.
aMSM denotes men who have sex with men.
bIn this Tabriz, Iran, study (Sarafraz et al., 2013), 26 samples were reported as suspicious cases in trichrome-stained smears.
Table 1. Global prevalence of D. fragilis infections in stool samples from various sources
Conflicting reports exist regarding the age-group distribution of D. fragilis infections. Two
studies, Danish and Canadian, reported a high infection rate in subjects aged between 16 and
20 years, respectively [25, 60]. On the other hand, despite being statistically insignificant, Rayan
et al. (2007) reported a higher infection rate in individuals aged between 30 and 40 years [24].
In contrast, other investigators reported a higher incidence rate in children and in less than 20
years old [8, 16, 27, 29, 63, 74, 95, 100]. In a recent study by Al-Hindi and Abu Shammala (2013)
in the Gaza strip regarding age, children less than 5 years of age were reported to have a
prevalence of 11.3%, while the age-group 20–26 years had 15.4% [4]. This is in contrast to findings
by Girginkardesler et al. (2003), who reported that D. fragilis infection was higher among children
than adult [29]. No plausible explanation to these variations in age distribution of D. fragilis
incidences is proposed. Nevertheless, hygiene and modest sanitation have been suggested as
likely to prejudice groups to infections with D. fragilis and other intestinal protozoa irrespec‐
tive of age making the fecal oral route as the probable route of transmission [12, 24, 53, 101].
With respect to the association between gender and D. fragilis infections, numerous studies
report dissimilar trends. While several investigators report more infection incidences in females
than males [16, 24, 55, 57, 86, 95], other studies describe a drift towards males in certain age-
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groups [4, 8, 60]. For more details on the subject, the reader is advised to consult the review by
Barratt et al. (2011) [12].
5. Pathogenicity and clinical symptoms of dientamoebiasis
Originally proposed as a pathogen in 1936 by Hakansson, there still remains some reluctance
by many investigators accepting D. fragilis as a pathogen [102, 103]. For example, in a recent
retrospective case-control study in the Netherlands elucidating the clinical importance of D.
fragilis in children with chronic abdominal pain, De Jong et al. (2014) detected D. fragilis in
43.2% of patients with chronic abdominal pain and in 50.6% in the controls (without gastro‐
intestinal symptoms) (p = 0.255) [104]. Thus, there are no significant differences in symptoms
comparing children with and without D. fragilis infection. Furthermore, no relation was found
between clinical and microbiological response after treatment for D. fragilis in the same study,
suggesting that there is no association between chronic abdominal pain D. fragilis infection.
Nevertheless, many current studies have acknowledged and confirmed the pathogenic
potential of D. fragilis. It is often detected in the feces of patients suffering from gastrointestinal
tract disorders and presenting symptoms such as loose stools, diarrhea, urgency to defecate,
vomiting, nausea, anorexia, weight loss, abdominal pain, and fever [6–9, 11, 21, 29, 105, 106].
Many investigators have reported the tendency for this parasite to cause persistent diarrhea
[9, 55]. An example of a study confirming the pathogenic role of D. fragilis is an Italian study
in 2007, where Crotti and D’Annibale found that between 3.4% and 4.1% of patients with
various bowel complaints carried Dientamoeba [55, 57]. Another report corroborating the
pathogenic potential of the organism is an Australian study in which 5.4% (35/650) of patients
with bowel disorders were reported to have Dientamoeba in their stools, with 83.3% of them
suffering from diarrhea [10]. Furthermore, Dientamoeba has been linked it with irritable bowel
syndrome (IBS) [22, 97, 105]. Patients carrying Dientamoeba may also experience eosinophilia
[10, 63, 64, 103, 106, 107].
6. Treatment of D. fragilis infections
While still not recognized as a pathogen, the ability to resolve associated symptoms by
eradicating D. fragilis using different drugs provides some proof for its possible pathogenic
nature [6, 16, 20, 69, 102, 103, 108–110]. There is still no agreement as to the best regimen for
the complete elimination of the organism. Stark et al. (2010b) and Preiss et al. (1990) reported
a treatment ineffectiveness and/or relapse of dientamoebiasis following the use of metronida‐
zole only [11, 64]. In a recent Danish randomized trial, 96 children in Denmark with D.
fragilis infection and chronic gastrointestinal symptoms were treated with a 10-day course of
metronidazole or placebo [111]. Change in gastrointestinal symptoms following treatment did
not differ significantly between the groups. Eradication of D. fragilis was significantly greater
in the metronidazole group as assessed by PCR 2 weeks after completion of therapy, although
PCR positivity rebounded by 8 weeks after completion of therapy to levels comparable with
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those seen in placebo recipients. The eradication of D. fragilis was significantly greater in the
metronidazole group, although it declined rapidly from 62.5% 2 weeks after end of treatment
to 24.9% 8 weeks after end of treatment. The findings of the study did not provide evidence to
support routine metronidazole treatment of D. fragilis-positive children with chronic gastro‐
intestinal symptoms. However, the complete resolution of symptoms and elimination of the
organism were noted following the administration of either iodoquinol, paromomycin, or a
combination of the two [11, 107]. Most recently, Halkjær et al. (2015) described a case history
of a 16-year-old Danish patient who had suffered severe abdominal discomfort and flatulence
through his lifetime following infection with D. fragilis. The patient was treated initially with
a high dose of metronidazole, which eradicated the parasite and kept him without symptoms
for 1 year [112]. However, recurrence of the symptoms and recurrence of the D. fragilis infection
were thereafter treated successfully with paromomycin [112]. Other drugs that are also
reported to effectively eradicate the parasite leading to clinical cure included oxytetracycline,
doxycycline, tinidazole, secnidazole, ornidazole, and erythromycin [29, 30, 64, 102, 113].
Despite the lack of randomized controlled trial data, the literature suggests paromomycin is a
more efficacious agent than metronidazole [6, 11, 114]. New potential therapeutic compounds
are constantly being screened for by investigators. More recently, Stark et al. (2014) have shown
that there is no therapeutic response against dientamoebiasis with benzimidazoles (such as
albendazole and mebendazole) [115].
7. Role of genetic characteristics of the infecting strains in the pathogenesis
of dientamoebiasis
The outcome of an infection may depend on several factors, among which the genetic charac‐
teristics of the specific pathogen have been identified as an important one. The virulence and
disease outcome has been linked to the genotypes of few parasites such as Entamoeba histoly‐
tica and Giardia lamblia [116–124]. Despite its inability to ascertain correlation between geno‐
type and disease outcome, evidence emerged using the ssu rRNA gene of at least two
genetically distinct variants (genotypes 1 and 2) of D. fragilis are in existence [6, 9, 20, 125,
126]. Thus, in the case of D. fragilis infections, the ssu rRNA gene demonstrated inferiority as
a tool for molecular epidemiological studies [127]. Accordingly, new molecular tools were
employed to demonstrate the association between variants and clinical disease outcome. One
such tool is the use of C-profiling in which the cysteine nucleotide pattern is compared between
samples for evidence of genetic variation on the internal transcribed spacer regions (ITS1 and
ITS2) of the ribosomal gene [128]. These regions are noncoding sequences reported to be
suitable for molecular characterization of phylogenetically related organisms [129]. Bart et al.
(2008) and Stark and his group (2009) documented the occurrence in variations of ITS1 in D.
fragilis isolates [21, 130]. Furthermore, a correlation between certain ITS1 variants and disease
outcome was reported [130]. Recently, Barratt et al. (2010) found that the growth of Dienta‐
moeba in certain media formulations varied between different isolates, and while all Dienta‐
moeba isolates described by Barratt and colleagues were from patients with gastrointestinal
complaints, this work indicates that phenotypic diversity exists in Dientamoeba and that the
variation noted is likely to have a genetic basis. Nevertheless, it is still unclear whether the two
genotypes differ in their pathogenicity [131].
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8. Diagnosis of dientamoebiasis
While it is difficult to identify the trophozoites of D. fragilis morphologically, the only diag‐
nostic tool used to detect D. fraglis is microscopy using permanent stained smears. A large
variety of stains have been used for the microscopic examination of E. fragilis. However, the
most commonly used that also give much clearer images of the parasites are the trichrome and
the iron-hematoxylin stains. The sample should be fixed immediately after staining to avoid
degeneration of the trophozoites and staining should also occur sooner [107]. Trophozoites
range in size from 5 to 15 μm in length, from 9 to 12 μm in width, normally with 1–2 fragmented
nuclei with visible holes seen through the nucleus center. Smears may also contain tropho‐
zoites with the typical four nucleated form. No cyst stage has been recovered yet from humans
despite being observed in mice [23]. Even under ideal conditions, with prompt preservation
of stool and evaluation of permanent stained smears by experienced microscopists, Stark et al.
(2010a and 2011) reported a sensitivity of 34% and 38%, respectively, compared to PCR (real-
time and multiplex tandem—PCR) [10, 132]. Despite numerous studies reporting common
occurrence of D. fragilis infection, no clinical antigen-based, molecular, or serologic diagnostics
have been commercially developed to aid with laboratory identification to date, although
current molecular based methods are used for research [133]. The culture of D. fragilis has been
reported and is done in similar conditions as that of E. histolytica. Liquid or diphasic media is
used that can be in xenic or axenic conditions [10]. Another diphasic medium based on the
Loeffler’s slope has also been demonstrated, and Earle’s balanced salt solution (EBSS) has been
successfully used for the growth of D. fragilis [23].
Molecular diagnostic methods have been very instrumental for the improvement of our
understanding of different infections. There has been a significant gain in the development of
molecular methods for the detection of D. fragilis, although compared to other organisms, this
improvement has been much slower [32]. Several PCR protocols have been developed for the
detection of this organism mainly for research laboratories. These protocols vary from
conventional PCR to real-time PCR with increased sensitivity and specificity. Primers based
on the small ribosomal RNA gene have been developed for this purpose [9]. Verweij and
colleagues have developed a real-time PCR protocol using the 5.8S ribosomal RNA gene and
they showed that this method was both specific and sensitive [28]. A variation of PCR based
on the amplification of the internal transcribed spacer 1 region of D. fragilis has also been used
for the molecular characterization of the parasite [130]. The actin gene has also been used as a
target for the molecular characterization of this parasite [128]. Generally, the detection and/or
the molecular characterization of the parasite begin with DNA purification, which is a very
important and critical step in the amplification of the organism. Following DNA purification,
the PCR master mixed is prepared depending on the procedure to be used. In the case of
detection, the PCR protocol is generally sufficient. However, the molecular characterization
often requires a sequencing step with or without the purification of the PCR amplicons. Other
methods that have been used so far for the molecular characterization of D. fragilis include
high-resolution melt curve analysis (HRM) and restriction fragment length polymorphism
after amplification by PCR [9, 22].
Using HRM, Hussein and colleagues found 4 genetic profiles of which the first and most
common profile and the last profile (Profile 4) were more associated with diarrhea compared
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to the two middle profiles [22]. However, the ITS showed two major genotypes although there
were subgenotypes among those main categories. In another study, the ITS-1-5.8S rRNA gene-
ITS-2 region of D. fragilis was found to be highly variable and pyrosequencing method
identified 11 different alleles of the ITS-1 sequence showing the limitation of this gene in the
molecular characterization of the parasite [130]. Briefly, the use of molecular methods has
increased our knowledge on these organisms; much still remains to be discovered for the better
understanding of issues related to pathogenicity, diagnosis, and prognosis.
9. Conclusion
Known for almost a hundred years now, D. fragilis still remains a mysterious organism
although much has been learned. The use of molecular biology has clarified its classification
not as an amoeba but as a trichomonad. However, its pathogenicity as well as its genetic
diversity still remains to be clarified. Diagnosis particularly in developing areas of the world
where it could be common remains difficult because microscopy is not sensitive. This is made
to be even more difficult because of the uncertainty of the existence of a cyst stage, which so
far has only been demonstrated in very limited studies. Real-time PCR has been proven to be
more sensitive compared to all the other diagnostic methods, including conventional PCR,
microscopy, and culture. Further studies are needed, and collaboration between developing
and developed countries will help boost the research capacity on this infection and improve
our understanding of its distribution, pathogenicity, and immunology.
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